Mary J. Fidler

TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.

TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.

TL;DR: Installing maintenance pembrolizumab in patients with extensive‐stage SCLC after treatment with platinum and etoposide did not appear to improve median PFS compared with the historical data, however, the 1‐year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolexumab.

TL;DR: It is reported that unadjuvanted seasonal influenza vaccination via intratumoral, but not intramuscular, injection converts “cold” tumors to hot, generates systemic CD8+ T cell-mediated antitumor immunity, and sensitizes resistant tumors to checkpoint blockade, and proposes that antipathogen vaccines may be utilized for both infection prevention and repurposing as a cancer immunotherapy.

TL;DR: Chemo (PF) before surgery improved overall survival (OS) in those patients in most of the randomized trials and in meta-analyses and it was found that those patients with pathologic complete response to the initial treatment did better than those who had no improvement at all.